Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.930
+0.012 (0.41%)
Aug 7, 2026, 2:16 PM CET
Oryzon Genomics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -5.97 | -5.6 | -5.48 | -6.1 | -6.56 | -7.18 |
Depreciation & Amortization | 0.13 | 0.13 | 0.15 | 0.15 | 0.17 | 0.14 |
Other Adjustments | -0.32 | 0.91 | 1 | 1.84 | 1.11 | 0.23 |
Change in Receivables | -0.47 | - | 0.01 | 0.34 | 0.29 | -0.11 |
Changes in Inventories | -0.01 | - | 0 | 0 | 0.09 | 0.21 |
Changes in Accounts Payable | -1.07 | - | -0.92 | -1.13 | 0.87 | 1.21 |
Changes in Income Taxes Payable | 1.27 | 1.74 | - | 4.67 | 2.48 | 1.3 |
Changes in Other Operating Activities | 0.16 | -0.04 | -0.44 | -0.34 | -0.3 | 0.57 |
Operating Cash Flow | -4.91 | -2.36 | -5.69 | -0.57 | -1.85 | -3.63 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.03 | -11.04 | -0.1 | - | -0.08 | -0.18 |
Purchases of Intangible Assets | -7.84 | - | -7.71 | -14.5 | -14.2 | -11.59 |
Purchases of Investments | - | - | - | -0 | -0 | -0.01 |
Proceeds from Sale of Investments | - | 0 | - | 0 | 0 | 0.04 |
Investing Cash Flow | -14.67 | -11.04 | -7.81 | -14.5 | -14.27 | -11.72 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | 10.99 | 14.49 | 27.06 | 31.03 | 28.14 | 15.66 |
Long-Term Debt Repaid | -14.67 | -11.37 | -16.31 | -15.23 | -8.85 | -7.67 |
Net Long-Term Debt Issued (Repaid) | -3.68 | 3.12 | 10.75 | 15.8 | 19.28 | 7.99 |
Issuance of Common Stock | -0.02 | 28.65 | -0.15 | -0.16 | -0.08 | - |
Repurchase of Common Stock | - | - | 0.07 | -1.8 | -1 | - |
Net Common Stock Issued (Repurchased) | -0.02 | 28.65 | -0.08 | -1.96 | -1.08 | - |
Other Financing Activities | 4.46 | 4.36 | 1.58 | 0.08 | 0.14 | - |
Financing Cash Flow | 3.09 | 36.13 | 6.87 | 6.02 | 8.71 | 4.12 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.05 | -0 | -0.01 | -0 | 0 | 0.35 |
Net Cash Flow | -16.43 | 22.74 | -6.64 | -9.06 | -7.41 | -10.88 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -4.94 | -13.4 | -5.79 | -0.57 | -1.92 | -3.8 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | - | -114.75% | -76.48% | -4.01% | -12.05% | -35.26% |
Free Cash Flow Per Share | -0.06 | -0.18 | -0.09 | -0.01 | -0.04 | -0.07 |
Levered Free Cash Flow | -7.73 | -8.68 | 5.86 | 15.8 | 18.29 | 6.56 |
Unlevered Free Cash Flow | -22.16 | -11.86 | -4.2 | 0.86 | -0.31 | -1.32 |